These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 25019596)

  • 1. Quinolone-based HDAC inhibitors.
    Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
    Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
    Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
    Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
    Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
    ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
    Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
    Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
    Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
    Liu YM; Lee HY; Chen CH; Lee CH; Wang LT; Pan SL; Lai MJ; Yeh TK; Liou JP
    Eur J Med Chem; 2015 Jan; 89():320-30. PubMed ID: 25462248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of adamantane based highly potent HDAC inhibitors.
    Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
    Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
    Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
    Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
    Liu R; Wang J; Tang W; Fang H
    Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
    Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
    Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
    Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
    Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of Santacruzamate-A based analogues.
    Randino R; Gazzerro P; Mazitschek R; Rodriquez M
    Bioorg Med Chem; 2017 Dec; 25(24):6486-6491. PubMed ID: 29100734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
    Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.